Apogee Therapeutics surges 19% on positive eczema drug trial data
Phase 2 APEX trial shows durable response with less frequent dosing, positioning drug for Phase 3 in second half of 2026
Apogee Therapeutics shares surged 19% on Monday after the biotechnology company reported positive 52-week data from its Phase 2 APEX trial for an experimental eczema treatment, adding approximately $540 million to its market capitalization.
The stock rose $12.56 to $78.60, extending a rally that has more than doubled the company's value since its initial public offering. Apogee now commands a market capitalization of $4.55 billion, with 14 of 16 analysts rating the shares a buy and a consensus price target of $104.33 representing roughly 33% upside from current levels.
The trial evaluated zumilokibart (APG777), an anti-interleukin-13 (IL-13) monoclonal antibody for moderate-to-severe atopic dermatitis, a chronic inflammatory skin condition affecting millions of patients worldwide. The drug demonstrated durable maintenance of response at 52 weeks when administered every three or six months, with 75% and 85% of week 16 responders maintaining EASI-75—a measure of skin clearance—on the respective dosing schedules, according to the company's press release.
"These data demonstrate that we can maintain high levels of skin clearance and itch control with significantly less frequent dosing compared to current standard of care treatments," the company stated in the announcement. The data also showed deepening of response across lesional and itch endpoints through 52 weeks in the full patient population.
The less frequent dosing regimen represents a potential competitive advantage in the atopic dermatitis market, which is projected to reach $6.5 billion in 2026 and expand to $12.3 billion by 2032. Current leading therapies such as Sanofi and Regeneron's Dupixent require administration every two weeks, translating to up to 26 injections annually. Apogee's approach would require as few as two to four injections per year.
Dupixent, which generated approximately $15.5 billion in revenue in 2025 and accounts for about 65% of atopic dermatitis sales, dominates the market as an inhibitor of both IL-4 and IL-13 signaling. However, its patent protection begins expiring in 2030, creating an opening for next-generation therapies.
Eli Lilly recently entered the space with lebrikizumab (EBGLYSS), a selective IL-13 inhibitor that received FDA approval in 2024. Lilly reported positive Phase 3 data in pediatric patients in March, expanding the drug's addressable population. However, lebrikizumab still requires monthly dosing, positioning Apogee's extended-interval regimen as a potential differentiation factor.
"The 52-week data provide important validation for the durability of response and the tolerability profile of zumilokibart," analysts noted in research coverage of the announcement. "The dosing advantage could be a significant differentiator if maintained in Phase 3 trials."
Safety data from the 52-week study showed zumilokibart was well-tolerated, with adverse events generally consistent with the IL-13 inhibitor class. The most common treatment-emergent adverse events were noninfective conjunctivitis, upper respiratory tract infection, and nasopharyngitis.
Apogee said it plans to initiate Phase 3 trials in the second half of 2026, with a potential commercial launch targeted for 2029. The company, which has no approved products and no revenue, reported a net loss of $284 million for the trailing twelve months with zero trailing revenue, according to market data compiled by StockAnalysis.
The atopic dermatitis treatment landscape has evolved rapidly since Dupixent's approval in 2017, transforming management of a disease that previously relied primarily on topical steroids and immunosuppressants. More than 120 pipeline drugs are currently in development across over 100 companies, reflecting sustained investment in the space despite the presence of established market leaders.
Apogee's approach combines targeted IL-13 inhibition with extended half-life technology, which the company believes could address limitations of existing treatments including dosing frequency, injection burden, and loss of response over time. The 52-week data showing maintenance and deepening of response addresses a key question for long-term disease management in a chronic condition requiring indefinite therapy.